Pharmaceutical Technology Editors

The commission adopts 24 new and 72 revised texts for inclusion in the European Pharmacopoeia.

Emergent BioSolutions announced FDA approval of Anthrasil, an inhalable treatment that targets Anthrax toxins, as well as a contract with BARDA to develop NuThrax, an anthrax vaccine candidate.

The event will take place at the Jakarta International Expo, Indonesia from April 8–10, 2015.

The agency provides guidance on determining the need for environmental assessments for gene therapies, vectored vaccines, and viral and microbial products.

Guidance provides labeling standards and an implementation guide for electronic submission of lot distribution reports.

Recipharm expects to be rolling out further serialization projects during 2015.

The investments made in analytical and process development equipment will enable Laurus Synthesis to offer chemistry services to its clients.

International day for fighting infection sees European infection specialists advocating vaccines as a viable solution to tackle antimicrobial resistance.

UPS expands its special commodities program to more countries.

Member of parliament, Desmond Swayne, will officially open the 42,000-square-foot facility on March 20, 2015.

Sharon Johnson, senior vice president, Global Quality & Regulatory Affairs, will head the organization.

The new flow sensors, BioPAT Flow, enable precise, reproducible data to be collected on flow rates and mass balances without coming in contact with the medium during measurement.

The manufacture and scale up production mark a significant milestone in the commercialization route of Nanobiotix lead product, NBTXR3.

WuXi's new facility in Philadelphia will manufacture CAR T-cell therapies and other cancer immunotherapies.

NSF's consensus-based standard incorporates multiple regulatory and industry requirements into a single rigorous standard for the manufacturing and distribution of pharmaceutical excipients.

Penn Pharma's equipment addition meets growing need for continuous dry granulation and for handling of highly potent drugs.

Valeant announced that it would increase its original acquisition agreement with Salix to approximately $15.8 billion.

Remsima has demonstrated comparability to the reference product, Remicade, in terms of safety, efficacy, and quality.

McNeil-PPC pleads guilty in connection with adulterated infants' and children's over-the-counter liquid medications.

Dr. Reddy’s announced that it expanded its facilities to include a formulation development laboratory at its Miyapur, Hyperabad, India plant.

Astellas Pharma announced that it received FDA approval for its treatment of fatal invasive fungal infections in patients with blood cancers.

Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.

Baxter has bought SuppreMol, a German biopharmaceutical company that focuses on autoimmune treatments, for €200 million ($225 million USD).

BASF is expanding its Verbund site in Ludwigshafen to include production capacity for about 20 specialty amines.

AbbVie’s acquisition of Pharmacyclics establishes the combined company as an emerging leader in hematological oncology.

Survey reveals pharmaceutical and medical attitudes towards “KOL” terminology.

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

Teva announced that it would sell its Sellersville, Pennsylvania facility to G&W Laboratories.

Canon announced that it established Canon BioMedical, a wholly owned biomedical business to develop, manufacture, and market operations related to Canon’s life-science and molecular diagnostics platform.

Steve Nole joins Grand River Aseptic Manufacturing as director of manufacturing.